Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017536 (giardiasis)
 1,714 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Albendazole, a benzimidazole carbamate commonly used for the treatment and control of intestinal helminthic infections, is also useful for the treatment of giardiasis. Therefore, it is of interest to determine whether the drug has activity against other intestinal protozoa, such as E. histolytica. The present results demonstrate that albendazole inhibits the growth of E. histolytica trophozoites in axenic cultures and induces fine structural changes such as polyribosome aggregation and loss of cytoplasmic vacuoles at concentrations up to 10 micrograms/ml. The viability of E. histolytica trophozoites was not affected by the drug. In contrast, lower concentrations of albendazole showed dramatic effects on G. lamblia trophozoites. These included loss of adhesiveness, striking modifications of the overall morphology of giardias, disassembly of the ventral disk, and loss of viability after prolonged treatment. The results provide further evidence on the potent antigiardial activity of albendazole and indicate that, at the concentrations used, the drug has no antiamebic activity.
 ...
PMID:Effects of albendazole on Entamoeba histolytica and Giardia lamblia trophozoites. 134 Mar 23

When 239 (1982) and 361 (1991) five- and nine-year-old children in St. Kitts were assessed for the presence of parasitic infections, there were significant reductions in the prevalence of trichuriasis from 83% to 58%, of ascariasis from 24% to 8.6% and of giardiasis from 15% to 9.4%. Anthelminthic use, which appeared to be the most important responsible intervention tool, remained roughly at the same level at 59-51%. However, the types of anthelminthics used changed over the period. Piperazine citrate, which was used by 66% in 1982, only had 35% usage in 1991. Albendazole which was not used at all in 1982 was taken by 32% of the children in 1991 and at the same time use of laevo-tetramisole increased by 20% from 14%. Suggestions are made for an island-wide mass intervention programme to manage parasitic infections.
 ...
PMID:Significant changes in gastrointestinal tract parasitic infections in children of St. Kitts over the 9-year period 1982-1991. 850 8

Many different infections with protozoan and helminthic parasites are common global health problems. Several protozoa are responsible for opportunistic infections in patients with AIDS. The newly developed drug, albendazole, has a strong activity against many nematode and cestode parasites. In the case of echinococcosis, it reduces the viability of protoscolices and cysts. Its hepatic metabolite, albendazole sulfoxide, is active against the larval cestodes. In the case of neurocysticercosis, administration of either the standard treatment, praziquantel, or the newly developed drug, albendazole, reduces or eliminates tapeworm cysts in 80-90% of patients. Patients with numerous cysts and those in whom neurologic symptoms or intracranial hypertension develops after therapy against cysticerci should receive adjunctive therapy with dexamethasone. Mass chemotherapy with single doses of albendazole or the older drug, mebendazole, is feasible for school-age children to treat the soil-transmitted helminthiases (ascariasis, hook-worm infection, and trichuriasis). The newly developed drug, ivermectin, is more effective against chronic strongyloidiasis than albendazole. It has been used most extensively against river blindness. It greatly reduces the number of microfilariae in the skin and eyes but has no effect on sclerosing keratitis or chorioretinitis. Both drugs are available in the US on a compassionate-use basis from their manufacturers. Field trials show that ivermectin is also effective against lymphatic filariasis and Mansonella ozzardi. Praziquantel is effective against many trematode and cestode infections. It is the drug of choice for schistosomiasis. Albendazole was effective against giardiasis in children in Bangladesh but ineffective in adult travelers returning from tropical areas. It appears to effect symptomatic improvement of intestinal microsporidial infections in patients with AIDS. The newly developed drug, fumagillin, can ameliorate ocular microsporidiosis. The newly developed drug, paromycin, treats cryptosporidiosis. Trimethoprim-sulfamethoxazole treats cyclosporiasis and isosporiasis.
 ...
PMID:Antiparasitic drugs. 860 86

The adverse effects and treatment failures to some of the currently recommended drugs for giardia infection have given rise to the need for alternative antigiardial agents. In an open, randomized parallel group study, the safety and efficacy of albendazole was compared with that of metronidazole for the treatment of giardiasis in children. Sixty two children aged between 2-12 years were randomized to receive either albendazole suspension 400 mg daily for 5 days or metronidazole suspension 7.5 mg/kg thrice daily for 5 days. The mean days required for cure, as evident by absence of cysts and/or trophozoites in the stool specimen, was 3.7 + 1.4 and 4.5 + 1.1 days, respectively for children on albendazole and metronidazole therapy. Six children on metronidazole therapy developed anorexia 2 to 4 days after the treatment. Albendazole proved as effective as metronidazole in the treatment of giardia infection in children with the added advantage of absence of anorexia.
 ...
PMID:A comparative clinical trial of albendazole versus metronidazole in giardiasis. 861 54

The adverse effects and treatment failures to some of the currently recommended drugs for giardia infection have given rise to the need for alternative antigiardial agents. In an open, randomized parallel group study, the safety and efficacy of albendazole was compared with metronidazole for the treatment of giardiasis in children. Sixty four children of age ranging from 2-12 years was randomized to receive either albendazole suspension 400 mg daily for 5 days or metronidazole suspension 400 mg daily for 5 days or metronidazole suspension 7.5 mg/Kg thrice daily for 5 days. The mean days required for cure, as evident by absence of cysts and/or trophozoites in the stool specimen, were 3.7 +/- 1.4 and 4.5 +/- 1.1 days, respectively for children on albendazole and metronidazole therapy. Six children on metronidazole therapy developed anorexia 2 to 4 days after the treatment. Albendazole proved as effective as metronidazole in the treatment of giardia infection in children with the added advantage of the absence of anorexia.
 ...
PMID:A comparative clinical trial of albendazole versus metronidazole in children with giardiasis. 861 82

Bone marrow toxicosis was detected in a dog and cat following albendazole administration. Both animals were admitted with pancytopenia. In the dog, pancytopenia was attributed to severe panmarrow hypoplasia, whereas the cat had hypoplasia of erythroid and megakaryocytic series, but with a left-shifted granulocytic hyperplasia. Results of cytologic examination of bone marrow from both animals were compatible with acute injury. Both animals had been treated with albendazole for giardiasis prior to the onset of clinical signs. Bone marrow toxicosis was attributed to albendazole administration for the following reasons: this was the only or most recent drug administered, other causes of bone marrow toxicosis were not found, and both animals recovered rapidly with supportive care that consisted of fluid and antibiotic administration. Albendazole induced toxicosis appeared to be dose related in the dog and idiosyncratic in the cat. On the basis of the findings in this report, there is a potential for the development of albendazole induced bone marrow toxicosis in dogs and cats; therefore, veterinarians should exercise caution when using this drug.
 ...
PMID:Development of bone marrow toxicosis after albendazole administration in a dog and cat. 918 23

The parasitological, clinical efficacy and tolerability of albendazole in the treatment for both giardiasis and hookworm infection in a remote Aboriginal population was investigated. Albendazole at a dose rate of 400 mg daily for 5 days was highly effective in reducing hookworm egg numbers and both Giardia antigen and cysts. The 36.6% prevalence of Giardia prior to treatment fell to 12% between days 6 and 9, 15% for days 10-17 and rose to 28% between days 18 and 30. Tolerability and clinical efficacy were excellent. The effect of albendazole on hookworm was longer lasting than that on Giardia, reducing percent infection from over 76-2% on days 6-9 and zero by day 18-30 despite conditions highly conducive to rapid re-infection. We conclude that albendazole is highly efficacious against both parasites when used as described but that long term community benefit may require additional education programmes to avoid re-infection with Giardia although treatment strategies would seem appropriate for hookworm.
 ...
PMID:Efficacy of albendazole against Giardia and hookworm in a remote Aboriginal community in the north of Western Australia. 977 41

Albendazole and metronidazole were compared in 68 patients diagnosed positive for giardiasis. Albendazole 1200 mg, one dose was given to 24 patients, albendazole 400 mg twice a day for 3 days was given to 23 patients, and metronidazole 400 mg 3 times a day for 5 days to 21 patients. Response to therapy was monitored by clinical examination and analysis of fresh faecal samples on days 0, 3, 7 and 10. Response to the single dose of albendazole was 55%, to the divided dose of albendazole 70%, and to metronidazole 84%. The results show that albendazole, originally recommended for helminthic infection, can also be used in patients with mixed protozoal infection or for infections resistant to metronidazole.
 ...
PMID:Efficacy of albendazole in giardiasis. 1533 80

Albendazole, one of the more recently developed of the benzimidazole carbamate anthelmintics, has the broadest spectrum of activity of the benzimidazoles released to date. In this article, Jim Reynoldson, Andrew Thompson and John Horton discuss the role of this drug in the fight against giardiasis.
 ...
PMID:Albendazole as a future antigiardial agent. 1546 58

We examined the therapeutic effects of albendazole compared to metronidazole in 120 patients with giardiasis in Hamdan. Patients were randomized to receive albendazole (400 mg, once daily for 5 days) or metronidazole (250 mg, 3 times a day for 5 days). Demographic data of the patients, results of stool examination for Giardia trophozoites before and after treatment, and drug side-effects were recorded. After treatment 6 (10.0%) of the albendazole group had trophozoites compared with 14 (23.3%) of metronidazole group (P < 0.05). Patients in the albendazole group had fewer side-effects while 43.3% of the metronidazole group experienced a metallic taste and 35.0% experienced loss of appetite. Albendazole is an easy, safe and effective treatment for giardiasis.
 ...
PMID:Albendazole versus metronidazole in the treatment of patients with giardiasis in the Islamic Republic of Iran. 1733 92


1 2 Next >>